These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1015 related articles for article (PubMed ID: 35750137)

  • 21. Hepatic inflammatory responses in liver fibrosis.
    Hammerich L; Tacke F
    Nat Rev Gastroenterol Hepatol; 2023 Oct; 20(10):633-646. PubMed ID: 37400694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune-metabolic interactions in homeostasis and the progression to NASH.
    Hoogerland JA; Staels B; Dombrowicz D
    Trends Endocrinol Metab; 2022 Oct; 33(10):690-709. PubMed ID: 35961913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
    Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extracellular Vesicles as Inflammatory Drivers in NAFLD.
    Srinivas AN; Suresh D; Santhekadur PK; Suvarna D; Kumar DP
    Front Immunol; 2020; 11():627424. PubMed ID: 33603757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
    Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
    Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disruption of hepatic small heterodimer partner induces dissociation of steatosis and inflammation in experimental nonalcoholic steatohepatitis.
    Magee N; Zou A; Ghosh P; Ahamed F; Delker D; Zhang Y
    J Biol Chem; 2020 Jan; 295(4):994-1008. PubMed ID: 31831621
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Macrophages in metabolic associated fatty liver disease.
    Alharthi J; Latchoumanin O; George J; Eslam M
    World J Gastroenterol; 2020 Apr; 26(16):1861-1878. PubMed ID: 32390698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Macrophage heterogeneity role in NAFLD and NASH disease progression].
    Yang T; Wang X; Jiang LF; Li J
    Zhonghua Gan Zang Bing Za Zhi; 2023 Jul; 31(7):770-775. PubMed ID: 37580264
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The immune response as a therapeutic target in non-alcoholic fatty liver disease.
    Ortiz-López N; Fuenzalida C; Dufeu MS; Pinto-León A; Escobar A; Poniachik J; Roblero JP; Valenzuela-Pérez L; Beltrán CJ
    Front Immunol; 2022; 13():954869. PubMed ID: 36300120
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identifying a distinct fibrosis subset of NAFLD via molecular profiling and the involvement of profibrotic macrophages.
    He W; Huang Y; Shi X; Wang Q; Wu M; Li H; Liu Q; Zhang X; Huang C; Li X
    J Transl Med; 2023 Jul; 21(1):448. PubMed ID: 37415134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNAs in the pathogenesis and treatment of progressive liver injury in NAFLD and liver fibrosis.
    Su Q; Kumar V; Sud N; Mahato RI
    Adv Drug Deliv Rev; 2018 Apr; 129():54-63. PubMed ID: 29391222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endoplasmic reticulum stress in innate immune cells - a significant contribution to non-alcoholic fatty liver disease.
    Zhou L; Shen H; Li X; Wang H
    Front Immunol; 2022; 13():951406. PubMed ID: 35958574
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Manifold Roles of Ceramide Metabolism in Non-Alcoholic Fatty Liver Disease and Liver Cancer.
    Wang K; Wei Y; Xu R; Li Y; Mao C
    Adv Exp Med Biol; 2022; 1372():157-168. PubMed ID: 35503180
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pattern recognition receptors in the development of nonalcoholic fatty liver disease and progression to hepatocellular carcinoma: An emerging therapeutic strategy.
    Huang C; Zhou Y; Cheng J; Guo X; Shou D; Quan Y; Chen H; Chen H; Zhou Y
    Front Endocrinol (Lausanne); 2023; 14():1145392. PubMed ID: 37020586
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatic fibrosis: Targeting peroxisome proliferator-activated receptor alpha from mechanism to medicines.
    Gong L; Wei F; Gonzalez FJ; Li G
    Hepatology; 2023 Nov; 78(5):1625-1653. PubMed ID: 36626642
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging Roles of T Cells in the Pathogenesis of Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
    Hirsova P; Bamidele AO; Wang H; Povero D; Revelo XS
    Front Endocrinol (Lausanne); 2021; 12():760860. PubMed ID: 34777255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
    McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
    JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Wu J
    Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-alcoholic fatty liver disease.
    Powell EE; Wong VW; Rinella M
    Lancet; 2021 Jun; 397(10290):2212-2224. PubMed ID: 33894145
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease.
    Svegliati-Baroni G; Pierantonelli I; Torquato P; Marinelli R; Ferreri C; Chatgilialoglu C; Bartolini D; Galli F
    Free Radic Biol Med; 2019 Nov; 144():293-309. PubMed ID: 31152791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.